Kaloun; El Bachir

Patent Applications and Registrations

Patent applications and USPTO patent grants for Kaloun; El Bachir.The latest application filed is for "hemi-synthetic trilobine analogs for use as a drug".

Company Profile

4.14.15

Kaloun; El Bachir - Roquettes FR
Kaloun; El Bachir - Cergy Saint Christophe FR
Kaloun; El Bachir - Cergy Saint Christoph FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Hemi-synthetic trilobine analogs for use as a drug Grant 10,544,156 - Halby , et al. Ja	2020-01-28
Flavagline derivatives Grant 10,519,125 - Marion , et al. Dec	2019-12-31
Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK Grant 10,323,043 - Kaloun , et al.	2019-06-18
Hemi-synthetic Trilobine Analogs For Use As A Drug App 20190062339 - HALBY; Ludovic ; et al.	2019-02-28
Flavagline derivatives Grant 10,047,064 - Marion , et al. August 14, 2	2018-08-14
Isoquinolinone derivatives useful in the treatment of cancer Grant 9,944,641 - Kaloun , et al. April 17, 2	2018-04-17
Flavagline Derivatives App 20180086729 - MARION; Frederic ; et al.	2018-03-29
Derivatives Of Macrocyclic N-aryl-tricyclopyrimidine-2-amine Polyethers As Inhibitors Of Ftl3 And Jak App 20170283432 - KALOUN; El Bachir ; et al.	2017-10-05
Derivatives Of Macrocyclic N-aryl-2-amino-4-aryl-pyrimidine Polyethers As Inhibitors Of Ftl3 And Jak App 20170281622 - KALOUN; El Bachir ; et al.	2017-10-05
Isoquinolinone Derivatives Useful In The Treatment Of Cancer App 20170240544 - KALOUN; El Bachir ; et al.	2017-08-24
Flavagline Derivatives App 20170137400 - MARION; Frederic ; et al.	2017-05-18
Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk Grant 9,428,510 - Kruczynski , et al. August 30, 2	2016-08-30
DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING Trk App 20150266880 - Kruczynski; Anna ; et al.	2015-09-24
Tri- and tetracyclic pyrazolo[3,4-B]pyridine compounds as antineoplastic agent Grant 9,085,575 - Rabot , et al. July 21, 2	2015-07-21
Pyrazolopyridine derivatives as anticancer agent Grant 8,889,711 - Bedjeguelal , et al. November 18, 2	2014-11-18
Substituted pyrazolo[3,4-b]pyridines as medicaments Grant 8,883,821 - Kaloun , et al. November 11, 2	2014-11-11
Tri - And Tetracyclic Pyrazolo[3,4-b]pyridine Compounds As Antineoplastic Agent App 20140031362 - Rabot; Remi ; et al.	2014-01-30
Derivatives Of Azaindazole Or Diazaindazole Type As Medicament App 20130172360 - Kaloun; El Bachir ; et al.	2013-07-04
Pyrroloquinoline derivatives and their use as protein kinases inhibitors Grant 8,426,437 - Bienayme , et al. April 23, 2	2013-04-23
Derivatives Of Azaindazole Or Diazaindazole Type As Medicament App 20130085144 - KALOUN; El Bachir ; et al.	2013-04-04
Pyrazolopyridine Derivatives As Anticancer Agent App 20120245170 - Bedjeguelal; Karim ; et al.	2012-09-27
Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors App 20090042876 - Bienayme; Hugues ; et al.	2009-02-12
3-(4-oxo-4H-chromen-2-yl)-(1H)-quinolin-4-one derivatives, method for preparing same and pharmaceutical compositions containing same Grant 7,339,061 - Brion , et al. March 4, 2	2008-03-04
Novel 3-(4-oxo-4h-chromen-2-yl)-(1H)-quinolin-4-one derivatives, method for preparing same and pharmaceutical compositions containing same App 20060063801 - Brion; Jean-Daniel ; et al.	2006-03-23

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.